Shutting Down a ‘Dark Kinase’ May Defeat Treatment-Resistant Cancers
A multi-faceted study from Department of Pharmacology and Cancer Biology researchers shows for the first time that blocking an under-studied enzyme called PKN2 may be the key to stopping aggressive, treatment-resistant cancers.
